Gynecologic Cancers

Pembrolizumab/lenvatinib yielded a 40% ORR in patients with recurrent gynecologic clear cell carcinoma, including those with prior anti-angiogenic therapy.

Data from the KEYNOTE-B96 trial support the FDA approval of the pembrolizumab regimen in these gynecologic malignancies.

No grade 3 or greater treatment-related adverse effects or long-term safety signals emerged with gemogenovatucel-T in this ovarian cancer group.

The safety profile of atezolizumab plus bevacizumab and chemotherapy in this phase 3 trial was comparable with prior reports of the agents.

BI-1808 plus pembrolizumab was safe and well-tolerated among patients with recurrent ovarian cancer.

Among 35 patients with ovarian cancer treated with an antibody-based combination, the overall response rate was 23%, with a clinical benefit rate of 31%.

Pooled analysis data from the phase 1 JSKN003-101 and phase 1/2 JSKN003-102 trials support the regulatory decision.

Fuzuloparib monotherapy and as a combination with apatinib improved PFS as maintenance therapy in patients with ovarian cancer harboring BRCA1/2 mutations.

Investigators noted 1 instance of rectovaginal fistula in the PEG gel arm, although rapid postoperative recovery occurred.

Although both immune priming strategies numerically improved ORR and PFS vs olaparib monotherapy, the study was not powered for comparisons between arms.

Deeper short-term declines in quality of life occurred when combining cisplatin with radiation for those with intermediate-risk cervical cancer.

Fertility-sparing surgery showed comparable efficacy vs hysterectomy in early-stage cervical cancer, with a 5-year RFS rate of 92% vs 96.4%, respectively.

The median PFS for patients with ovarian cancer who received niraparib maintenance in the real-world setting was 25.7 months.

The 3-year DFS rate was 96.9% in patients who received sentinel-lymph node biopsy alone vs 94.6% in those who received lymphadenectomy.

Although the study was underpowered due to a small sample size, nonsignificant improvements in functional and social well-being occurred with MOST-S26.

The Promega OncoMate MSI Dx Analysis System was previously approved to identify Lynch syndrome in patients with CRC.

Findings from 2 studies showed that onetime cell therapies can elicit complete tumor regression in patients with advanced epithelial cancers.

Phase 3 data demonstrate PD-L1 positivity and BRCA mutation status as prognostic for improved overall survival regardless of treatment arm.

The FDA decision is based on data from a pooled analysis of phase 1/2 study data from 2 trials evaluating the agent in advanced/metastatic PROC.

Granulosa cell tumors exhibit late recurrence and rare hepatic metastasis, emphasizing the need for lifelong surveillance in affected patients.

Grade 3 or 4 AEs were experienced by 42.9% of patients who received cisplatin plus radiation compared with 15.3% of patients who received radiation alone.

Approximately half of the patients who received raludotatug deruxtecan in the phase 2/3 REJOICE-Ovarian01 trial achieved an objective response.